A Boston Globe report (below) focuses on three recent reports in the Journal of the American Medical Association (JAMA) by Harvard researchers who violated the journal’s disclosure policy by failing to disclose their financial ties to companies that had the most to gain from their purported findings.
8, 362 consumers of Lilly’s top-selling drug that produces diabetes–among other life-threatening effects–can expect between $5,000 to "well over $100,000 a person" depending upon the harm suffered.
The full impact on six healthy volunteers who took part in a catastrophic experiment that nearly killed them is ever so slowly coming to light.
Two probing first rate investigative reports document how psychiatry’s treatments are shaped by "opinion leaders" whose professional recommendations are compromised by their substantial, largely undisclosed, financial ties to drug companies.
For almost two decades Eli Lilly has denied that evidence exists demonstrating that its antidepressant Prozac induced violence and suicidality.
Once again, the New England Journal of Medicine (July 13, 2006) has had to eat crow after it published false and misleading clinical trial findings.
It is difficult to believe this latest announcement laying claim to a new "under treated" psychiatric disorder–Intermittent Explosive Disorder (IED) is not a parody !!
This is documented evidence of major medical malpractice.
An investigative report in The Philadelphia Inquirer examined pharmaceutical company ties to six, tax exempt organziations that identify themselves as “patient advocacy” groups, "Each a leading advocate for patients in a disease area.”
Our criticism of a high risk, speculative drug experiment conducted on healthy children and adolescents at Yale University’s Psychiatric Institute was validated by a federal investigation: and our criticism is now validated by the principle investigator, Dr. Thomas McGlashan.
Health Canada has taken constructive step to warn people with high blood pressure, heart disease and other medical ailments NOT to take psychostimulant drugs–which are essentially amphetamines.
GSK’s acknowledgement refutes the recent claims made in the official organ of the American Psychiatric Association, The American Journal of Psychiatry.
